133 related articles for article (PubMed ID: 17497733)
1. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
Autissier V; Damment SJ; Henderson RA
J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
[TBL] [Abstract][Full Text] [Related]
2. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
3. Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study.
Schumacher SP; Schurgers LJ; Vervloet MG; Neradova A
Nephrology (Carlton); 2019 Feb; 24(2):221-226. PubMed ID: 29479762
[TBL] [Abstract][Full Text] [Related]
4. Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment.
Coppolino G; Lucisano S; Rivoli L; Fuiano G; Villari A; Villari I; Leonello G; Lacquaniti A; Santoro D; Buemi M
Ther Apher Dial; 2015 Oct; 19(5):471-6. PubMed ID: 25866250
[TBL] [Abstract][Full Text] [Related]
5. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
Keith MS; Wilson RJ; Preston P; Copley JB
Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
[TBL] [Abstract][Full Text] [Related]
6. Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
Keith MS; Sibbel S; Copley JB; Wilson RJ; Brunelli SM
Clin Ther; 2014 Oct; 36(10):1431-42.e1. PubMed ID: 25150194
[TBL] [Abstract][Full Text] [Related]
7. The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
Wilson RJ; Keith MS; Preston P; Copley JB
Adv Ther; 2013 Dec; 30(12):1100-10. PubMed ID: 24307220
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
Zhou T; Li H; Xie W; Lin Z
Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
[TBL] [Abstract][Full Text] [Related]
9. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
Behets GJ; Dams G; Damment SJ; Martin P; De Broe ME; D'Haese PC
Am J Physiol Renal Physiol; 2014 Jan; 306(1):F61-7. PubMed ID: 24197066
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
Yaguchi A; Yonekubo S; Maruyama I; Tatemichi S; Maruyama K; Kobayashi M
Drug Res (Stuttg); 2016 May; 66(5):262-9. PubMed ID: 26761712
[TBL] [Abstract][Full Text] [Related]
11. Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients.
Filiopoulos V; Koutis I; Trompouki S; Hadjiyannakos D; Lazarou D; Vlassopoulos D
Ther Apher Dial; 2011 Feb; 15(1):20-7. PubMed ID: 21272248
[TBL] [Abstract][Full Text] [Related]
12. Novel dosage forms and regimens for sevelamer-based phosphate binders.
Duggal A; Hanus M; Zhorov E; Dagher R; Plone MA; Goldberg J; Burke SK
J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
[TBL] [Abstract][Full Text] [Related]
13. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.
Martin P; Wang P; Robinson A; Poole L; Dragone J; Smyth M; Pratt R
Am J Kidney Dis; 2011 May; 57(5):700-6. PubMed ID: 21354682
[TBL] [Abstract][Full Text] [Related]
14. Phosphate Binders Derived from Natural Ores Contain Many Kinds of Metallic Elements Besides Their Active Ingredient Metals.
Nagano N; Minegishi A; Ito K; Ando T; Tsutsui T; Ogawa T
Ther Apher Dial; 2018 Dec; 22(6):630-634. PubMed ID: 29989312
[TBL] [Abstract][Full Text] [Related]
15. Improving phosphate-binder therapy as a way forward.
Hutchison AJ
Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic use of the phosphate binder lanthanum carbonate.
Barton Pai A; Conner TA; McQuade CR
Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):71-81. PubMed ID: 19236230
[TBL] [Abstract][Full Text] [Related]
17. Novel oral phosphate binder with nanocrystalline maghemite-phosphate binding capacity and pH effect.
Nguyen TM; Müller RH; Taupitz M; Schnorr J; Hamm B; Wagner S
Int J Pharm; 2015 Mar; 482(1-2):21-6. PubMed ID: 25448551
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.
Arenas MD; Rebollo P; Malek T; Moledous A; Gil MT; Alvarez-Ude F; Morales A; Cotilla E
J Nephrol; 2010; 23(6):683-92. PubMed ID: 20540040
[TBL] [Abstract][Full Text] [Related]
19. Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study.
Neradova A; Schumacher SP; Hubeek I; Lux P; Schurgers LJ; Vervloet MG
BMC Nephrol; 2017 May; 18(1):149. PubMed ID: 28464802
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets.
Yang Y; Bykadi S; Carlin AS; Shah RB; Yu LX; Khan MA
J Pharm Sci; 2013 Apr; 102(4):1370-81. PubMed ID: 23334989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
